Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Noa E Wijnen, Joost B Koedijk, Kim Klein, Maaike Luesink, Bianca F Goemans, C Michel Zwaan & Gertjan JL Kaspers. (2023) Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin. OncoTargets and Therapy 16, pages 297-308.
Read now
Read now
Min Lin & Baoan Chen. (2018) Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). Drug Design, Development and Therapy 12, pages 1009-1017.
Read now
Read now
Kim Klein, Valérie de Haas & Gertjan J. L. Kaspers. (2018) Clinical challenges in de novo pediatric acute myeloid leukemia. Expert Review of Anticancer Therapy 18:3, pages 277-293.
Read now
Read now
Francisco Bautista, Jasper Van der Lugt, Pamela R. Kearns, Francis J. Mussai, C. Michel Zwaan & Lucas Moreno. (2016) The development of targeted new agents to improve the outcome for children with leukemia. Expert Opinion on Drug Discovery 11:11, pages 1111-1122.
Read now
Read now
Articles from other publishers (10)
Sarah Blain, Noémie Payette, Henrique Bittencourt & Donna L. Johnston. (2023) Gemtuzumab Ozogamicin Monotherapy Is a Well-tolerated Palliative Chemotherapy Option in Pediatric Multiply Relapsed Acute Myeloid Leukemia: A Multicenter Case Series and Review of the Literature. Journal of Pediatric Hematology/Oncology 45:8, pages 436-444.
Crossref
Crossref
Eman T. Al-Antary, Avanti Gupte, Jenna Carter, Mirna Kaafarani, Mackenzie Howard, Holly Edwards, Yubin Ge & Jeffrey W. Taub. (2023) Curing childhood cancer the “Natural” Way: Nature as the source of chemotherapy agents. Biochemical Pharmacology 213, pages 115630.
Crossref
Crossref
Chloé Dhunputh, Marion Strullu, Arnaud Petit, Maria Merched, Marlène Pasquet, Saba Azarnoush, Guy Leverger & Stéphane Ducassou. (2022)
Single‐dose (4.5 mg/m
2
) gemtuzumab ozogamicin in combination with fludarabine, cytarabine and anthracycline as reinduction therapy in relapsed or refractory paediatric acute myeloid leukaemia
. British Journal of Haematology 198:2, pages 373-381.
Crossref
Crossref
Yuji Yamada, Tomoo Osumi, Motohiro Kato, Yoko Shioda, Chikako Kiyotani, Keita Terashima, Akira Hayakawa, Yuka Iijima-Yamashita, Keizo Horibe, Kimikazu Matsumoto & Daisuke Tomizawa. (2022) Gemtuzumab Ozogamicin Followed by Unrelated Cord Blood Transplantation With Reduced-intensity Conditioning for a Child With Refractory Acute Promyelocytic Leukemia. Journal of Pediatric Hematology/Oncology 44:4, pages 178-180.
Crossref
Crossref
Zhiwen Fu, Shijun Li, Sifei Han, Chen Shi & Yu Zhang. (2022) Antibody drug conjugate: the “biological missile” for targeted cancer therapy. Signal Transduction and Targeted Therapy 7:1.
Crossref
Crossref
Kevin O. McNerney, Katelyn Oranges, Alix E. Seif, Benjamin Oshrine, Bonnie Ky, Kimberly Y. Lin, Kelly D. Getz & Richard Aplenc. (2022) Acute Left Ventricular Dysfunction Following Gemtuzumab Ozogamicin in Two Pediatric AML Patients. Journal of Pediatric Hematology/Oncology 44:2, pages e507-e511.
Crossref
Crossref
Mohammed Gbadamosi, Soheil Meshinchi & Jatinder K Lamba. (2018) Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia. Future Oncology 14:30, pages 3199-3213.
Crossref
Crossref
Chen Wang, Pan Xu, Luyu Zhang, Jing Huang, Kongkai Zhu & Cheng Luo. (2018) Current Strategies and Applications for Precision Drug Design. Frontiers in Pharmacology 9.
Crossref
Crossref
Henrik Hasle & Gertjan J. L. Kaspers. (2017) Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review. British Journal of Haematology 176:2, pages 168-178.
Crossref
Crossref
Oussama Abla, Matthew A. Kutny, Anna Maria Testi, James H. Feusner, Ursula Creutzig, John GregoryJrJr, Brenda Gibson, Guy Leverger, Raul C. Ribeiro, Owen Smith, Franco Locatelli & Gertjan Kaspers. (2016) Management of relapsed and refractory childhood acute promyelocytic leukaemia: recommendations from an international expert panel. British Journal of Haematology 175:4, pages 588-601.
Crossref
Crossref